Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)- 6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
2. At 4140
3. At-4140
4. Ci 978
5. Ci-978
6. Pd 131501
7. Pd-131501
8. Zagam
1. 110871-86-8
2. Zagam
3. At-4140
4. Ci-978
5. Spara
6. Ci 978
7. Spfx
8. Pd 131501
9. Pd-131501
10. At 4140
11. 111542-93-9
12. Chebi:9212
13. 5-amino-1-cyclopropyl-7-((3s,5r)-3,5-dimethylpiperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
14. 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
15. 5-amino-1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
16. Q90aga787l
17. 5-amino-1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic Acid
18. Cis-5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
19. Esparfloxacino
20. Sparfloxacine
21. Sparfloxacinum
22. Nsc-759641
23. Mfcd00869619
24. Dsstox_cid_3590
25. Dsstox_rid_77097
26. Dsstox_gsid_23590
27. 3-quinolinecarboxylic Acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, Cis-
28. 5-amino-1-cyclopropyl-7-((3r,5s)-3,5-dimethylpiperazin-1-yl)-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
29. 5-amino-1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic Acid
30. Sparfloxacine [inn-french]
31. Sparfloxacinum [inn-latin]
32. Drg-0143
33. Esparfloxacino [inn-spanish]
34. Parox
35. Cas-110871-86-8
36. Zagam (tn)
37. Cp 103826
38. Sr-05000001521
39. Brn 3658018
40. Unii-q90aga787l
41. Sparfloxacin & Ru 40555
42. Pd 1315-1
43. Sparfloxacin (jan/usan/inn)
44. Liposome-encapsulated Sparfloxacin
45. Sparfloxacin,(s)
46. Ncgc00159333-02
47. Sparfloxacin [usan:inn:ban:jan]
48. Sparfloxacinhydrochloride
49. Pd131501
50. Rp-64206
51. Cp-103826
52. Sparfloxacin [mi]
53. Sparfloxacin [inn]
54. Sparfloxacin [jan]
55. Chembl850
56. Epitope Id:119065
57. Sparfloxacin [usan]
58. Sparfloxacin [vandf]
59. Schembl41311
60. Sparfloxacin [mart.]
61. Mls000759417
62. Sparfloxacin [who-dd]
63. Dtxsid9023590
64. Gtpl10860
65. Ci978
66. Hms2090n19
67. Hms3715j13
68. Sparfloxacin [orange Book]
69. Zinc538362
70. Bcp23886
71. Hy-b0308
72. Rkl10082
73. Sparfloxacin, >=98.0% (hplc)
74. Tox21_111580
75. At4140
76. Bbl010957
77. Bdbm50366822
78. S1884
79. Stk802067
80. Akos005622503
81. Tox21_111580_1
82. Ccg-221166
83. Db01208
84. Ks-5009
85. Nsc 759641
86. Sparfloxacin 100 Microg/ml In Methanol
87. Ncgc00166294-01
88. Ncgc00166294-02
89. Ncgc00166294-03
90. 3-quinolinecarboxylic Acid, 1,4-dihydro-5-amino-1-cyclopropyl-6,8-difluoro-7-(3,5-dimethyl-1-piperazinyl)-4-oxo-, Cis-
91. Ac-11574
92. Smr000466312
93. S0896
94. Sw199632-2
95. C07662
96. D00590
97. S-6990
98. Ab00639950-02
99. Ab00639950_03
100. Sparfloxacin, Vetranal(tm), Analytical Standard
101. 871s868
102. A802376
103. A894831
104. Q976559
105. Sr-01000759357
106. Sparfloxacin, Antibiotic For Culture Media Use Only
107. Sr-01000759357-2
108. Sr-05000001521-1
109. Sr-05000001521-2
110. Brd-k07612980-001-07-9
111. 4-bromo-1-(tert-butyl)-3-methyl-1h-pyrazole-5-carboxylicacid
112. 5-amino-1-cyclopropyl-6,8-difluoro-7-(cis-3,5-dimethyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid
113. 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl)-6,8- Difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid & Ru 40555
114. 5-amino-1-cyclopropyl-7-(cis-3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acid
115. 5-amino-1-cyclopropyl-7-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-quinoline-3-carboxylic Acid
116. 5-amino-1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylic Acid
117. 5-amino-1-cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-4-ium-1-yl]-6,8-difluoro-4-oxoquinoline-3-carboxylate
118. At-4140 Pound>>ci-978 Pound>>ci 978 Pound>>ci978 Pound>>at 4140 Pound>>at4140 Pound>>pd 131501 Pound>>pd131501 Pound>>pd-131501
| Molecular Weight | 392.4 g/mol |
|---|---|
| Molecular Formula | C19H22F2N4O3 |
| XLogP3 | 0.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | 392.16599690 g/mol |
| Monoisotopic Mass | 392.16599690 g/mol |
| Topological Polar Surface Area | 98.9 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 691 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae).
FDA Label
Sparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent in the same class as ofloxacin and norfloxacin. Sparfloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. Quinolones differ in chemical structure and mode of action from (beta)-lactam antibiotics. Quinolones may, therefore, be active against bacteria resistant to (beta)-lactam antibiotics. Although cross-resistance has been observed between sparfloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to sparfloxacin. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus.
Antitubercular Agents
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. (See all compounds classified as Antitubercular Agents.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01M - Quinolone antibacterials
J01MA - Fluoroquinolones
J01MA09 - Sparfloxacin
Absorption
Well absorbed following oral administration with an absolute oral bioavailability of 92%. Unaffected by administration with milk or food, however concurrent administration of antacids containing magnesium hydroxide and aluminum hydroxide reduces the oral bioavailability of sparfloxacin by as much as 50%.
Hepatic. Metabolized primarily by phase II glucuronidation to form a glucuronide conjugate. Metabolism does not utilize or interfere with the cytochrome P450 enzyme system.
Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance <50 mL/min).
The bactericidal action of sparfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
Market Place
ABOUT THIS PAGE
A Sparfloxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sparfloxacin, including repackagers and relabelers. The FDA regulates Sparfloxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sparfloxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sparfloxacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sparfloxacin supplier is an individual or a company that provides Sparfloxacin active pharmaceutical ingredient (API) or Sparfloxacin finished formulations upon request. The Sparfloxacin suppliers may include Sparfloxacin API manufacturers, exporters, distributors and traders.
click here to find a list of Sparfloxacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sparfloxacin DMF (Drug Master File) is a document detailing the whole manufacturing process of Sparfloxacin active pharmaceutical ingredient (API) in detail. Different forms of Sparfloxacin DMFs exist exist since differing nations have different regulations, such as Sparfloxacin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sparfloxacin DMF submitted to regulatory agencies in the US is known as a USDMF. Sparfloxacin USDMF includes data on Sparfloxacin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sparfloxacin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sparfloxacin suppliers with USDMF on PharmaCompass.
Sparfloxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sparfloxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sparfloxacin GMP manufacturer or Sparfloxacin GMP API supplier for your needs.
A Sparfloxacin CoA (Certificate of Analysis) is a formal document that attests to Sparfloxacin's compliance with Sparfloxacin specifications and serves as a tool for batch-level quality control.
Sparfloxacin CoA mostly includes findings from lab analyses of a specific batch. For each Sparfloxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sparfloxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Sparfloxacin EP), Sparfloxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sparfloxacin USP).
LOOKING FOR A SUPPLIER?
